Lots of interesting abstracts and cases were submitted for TCTAP 2026. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge!
ABS20251105_0006
Five-Year Major Adverse Cardiovascular Events of Patients After Stenting for Integrated-Backscatter IVUS-Identified Thin-Cap Fibrous Atheroma
By Masaya Ohta, Yukio Ozaki, Yu Yoshiki, Keiichi Miyajima, Naoyuki Kawashima, Yosuke Suzuki, Masayuki Koshikawa, Hideki Kawai, Takashi Muramatsu, Hideo Izawa
Presenter
Masaya Ohta
Authors
Masaya Ohta1, Yukio Ozaki1, Yu Yoshiki1, Keiichi Miyajima1, Naoyuki Kawashima1, Yosuke Suzuki1, Masayuki Koshikawa1, Hideki Kawai2, Takashi Muramatsu2, Hideo Izawa2
Affiliation
Fujita Health University Okakzaki Medical Center, Japan1, Fujita Health University Hospital, Japan2
View Study Report
ABS20251105_0006
Invasive Imaging (IVUS, OCT, NIRS, VH, etc)
Five-Year Major Adverse Cardiovascular Events of Patients After Stenting for Integrated-Backscatter IVUS-Identified Thin-Cap Fibrous Atheroma
Masaya Ohta1, Yukio Ozaki1, Yu Yoshiki1, Keiichi Miyajima1, Naoyuki Kawashima1, Yosuke Suzuki1, Masayuki Koshikawa1, Hideki Kawai2, Takashi Muramatsu2, Hideo Izawa2
Fujita Health University Okakzaki Medical Center, Japan1, Fujita Health University Hospital, Japan2
Background
We previously demonstrated that OCT-verified thin-cap fibro atheroma (TCFA) at the culprit site is detectable by utilizing integrated backscatter (IB)-IVUS during PCI. The aim of this study is to examine the five-year major adverse cardiovascular event (MACE) in patients after stenting for IB-IVUS-identified TCFA.
Methods
Of the 780 patients undergoing PCI, 166 consecutive patients with NSTE-ACS and CCS patients were enrolled to this study. Based on our previous study, IB-IVUS identified-TCFA was detected as a combination of lipid core abutting lumen, percentage of lipid area>53.6, and remodeling index >1.03. The primary endpoint was defined as a MACE (a composite of cardiovascular death, non-fatal myocardial infarction, any revascularization).
Results
During a median follow up of five years, the MACEs were observed in 32 patients (19%). Further, of these, 9 patients (28%) were stenting for IB-IVUS-identified TCFA. On Kaplan-Meier analysis, the incidences of the MACEs were observed higher in patients with culprit IB-TCFA than those without it (log lank p<0.01). Additionally, after adjustment of confounding factors, prior PCI (hazard ratio [HR] 2.43; 95% confidence interval [CI]: 1.18-5.01; p=0.02) and culprit IB-TCFA (HR 2.54; 95% CI: 1.16-5.56; p=0.02) were the independent predictors for the MACE.
Conclusion
Our study revealed that culprit IB-TCFA is likely to be a surrogate marker of MACE after successful PCI. Consequently, IB-IVUS technology may contribute to secondary prevention for patients with PCI.